ArticleHaematologica2024

Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment.

Surbhi Sidana et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.